The mechanism of action of the hypocholesterolemic drug p-(1-adamantyloxy)-aniline.
The effect of p-(1-adamantyloxy)-aniline (AOA) on the biliary secretion of cholesterol, bile salts, and phospholipids was studied in hypercholesterolemic rats. A second study was conducted using hypercholesterolemic rats with 14C-labeled cholesterol pools for the purpose of determining the effects of AOA on cholesterol metabolism. Treatment with AOA (100 mg/kg, orally) daily for 1 week resulted in the increased secretion of biliary cholesterol, but did not affect the secretion of bile salts or phospholipids. This treatment also resulted in an increase in the fecal excretion of 14C-labeled neutral and acidic sterols, and in reductions of both the total radioactivity in the liver and liver cholesterol. The data presented support the conclusion that the hypocholesterolemic action of AOA is due to the increased secretion of cholesterol into the bile and to the increased fecal excretion of cholesterol and bile salts.
D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001646:Bile / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D004032:Diet; D005243:Feces / Q000032:analysis; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism; D051381:Rats
C018807:4-(1-adamantyloxy)aniline; D000814:Aniline Compounds; D000924:Anticholesteremic Agents; D002784:Cholesterol; D000218:Adamantane